GSGaston Schechtmann

Gaston Schechtmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gaston Schechtmann has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Alp Tankisi

    Department of Anesthesiology Aarhus University Hospital Aarhus Denmark

    1 shared publication
  • Andreas Nørgaard Glud

    Center of Excellence in Focused Ultrasound, Department of Neurosurgery Aarhus University Hospital Aarhus Denmark

    1 shared publication
  • Anne Sofie Møller Andersen

    Center of Experimental Neuroscience, Aarhus University Hospital Aarhus Denmark

    1 shared publication
  • Birgitte Barrutia

    Department of Anesthesiology Aarhus University Hospital Aarhus Denmark

    1 shared publication
  • Bo Bergholt

    Center of Excellence in Focused Ultrasound, Department of Neurosurgery Aarhus University Hospital Aarhus Denmark

    1 shared publication
  • Bo Jespersen

    Department of Anesthesiology Aarhus University Hospital Aarhus Denmark

    1 shared publication

Latest Publications

  • Open Access

    Focused Ultrasound for Essential Tremor in Denmark: Results After 1 Year of Follow‐Up

    by Victor Hvingelby, Pernille Kjeldsen, Bo Bergholt, Gaston Schechtmann, Erik Hvid Danielsen, Mette Møller, Erik Lisbjerg Johnsen, Skirmante Mardosiene, Torben Ellegaard Lund, Dora Grauballe, et al.

    Background: Essential tremor (ET) is the most common hyperkinetic movement disorder. Magnetic resonance‐guided focused ultrasound thalamotomy (MRgFUSTh) has become an established therapy in drug‐refractory tremor as one treatment option. Here, we present the results of a large cohort of MRgFUSTh‐treated ET patients followed‐up 1 year post‐ablation. Objective: The primary endpoint durability of tremor reduction at 12 months at this timepoint. Methods: This was a single‐hospital cohort study. Prior to, and 12 months after, treatment, patients were rated according to the Fahn–Tolosa–Marin (FTM) scale, Quality of Life in Essential Tremor (QUEST) scale, Patient Global Assessment of Change (PGIC), as well as general health, well‐being, and factors relating to social and everyday activities. Finally, side effects and adverse event data were collected at 12 months. Results: The current cohort comprised 111 patients. Patients showed good response to MRgFUSTh with a mean decrease of 29.5 points in the total FTM‐score from pretreatment (95% CI: 26.3; 32.8, P < 0.0001) corresponding to 62.4% (95% CI: 56.4%; 68.5%). This meant a reduction in the FTM‐score of 13.8 points (± 5.2 points, 95% CI: 12.79; 14.73, P < 0.00001) or 85.2% (±24.2%, 95% CI: 80.70%; 89.78%) in the treated limb. For QUEST, symptoms improved by 20.9 points (95% CI: 12.1; 29.6, P < 0.0001) corresponding to a relative improvement of 54% (95% CI: 33.2%; 75.5%). Conclusion: Results showed clear and persistent tremor improvements as assessed by both clinicians and patients. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.